JP2018537519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537519A5 JP2018537519A5 JP2018536719A JP2018536719A JP2018537519A5 JP 2018537519 A5 JP2018537519 A5 JP 2018537519A5 JP 2018536719 A JP2018536719 A JP 2018536719A JP 2018536719 A JP2018536719 A JP 2018536719A JP 2018537519 A5 JP2018537519 A5 JP 2018537519A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- administered
- inhibitor
- hsp90
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237470P | 2015-10-05 | 2015-10-05 | |
| US62/237,470 | 2015-10-05 | ||
| PCT/US2016/055594 WO2017062520A1 (en) | 2015-10-05 | 2016-10-05 | Rational combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537519A JP2018537519A (ja) | 2018-12-20 |
| JP2018537519A5 true JP2018537519A5 (enExample) | 2019-11-28 |
| JP7132848B2 JP7132848B2 (ja) | 2022-09-07 |
Family
ID=57145064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536719A Expired - Fee Related JP7132848B2 (ja) | 2015-10-05 | 2016-10-05 | 癌の治療のための合理的併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180280397A1 (enExample) |
| EP (1) | EP3359196B1 (enExample) |
| JP (1) | JP7132848B2 (enExample) |
| KR (1) | KR20180058824A (enExample) |
| CN (1) | CN108472376A (enExample) |
| AU (1) | AU2016336351A1 (enExample) |
| BR (1) | BR112018006572A2 (enExample) |
| CA (1) | CA3000851A1 (enExample) |
| EA (1) | EA201890623A1 (enExample) |
| IL (1) | IL258494A (enExample) |
| MA (1) | MA47474A (enExample) |
| MX (1) | MX2018004112A (enExample) |
| TW (1) | TW201722422A (enExample) |
| WO (1) | WO2017062520A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016008418A (es) | 2013-12-23 | 2017-01-11 | Memorial Sloan Kettering Cancer Center | Metodos y reactivos para el radiomarcaje. |
| CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
| CN112641949A (zh) * | 2021-01-11 | 2021-04-13 | 深圳市人民医院(深圳市呼吸疾病研究所) | 一种含有pi3k抑制剂的药物组合物及其应用 |
| US20240371465A1 (en) * | 2023-05-02 | 2024-11-07 | National Central University | Method, system, and computer readable medium for post-translational modifications detection |
| CN116813622B (zh) * | 2023-05-19 | 2026-02-03 | 中国科学院基础医学与肿瘤研究所(筹) | 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004512381A (ja) | 2000-11-02 | 2004-04-22 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法 |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| ES2624982T3 (es) | 2011-07-08 | 2017-07-18 | Sloan-Kettering Institute For Cancer Research | Usos de inhibidores etiquetados HSP90 |
| KR102319582B1 (ko) | 2013-08-16 | 2021-11-04 | 메모리얼 슬로안 케터링 캔서 센터 | 선택적 ｇｒｐ９４ 저해제 및 이의 용도 |
| EA201692155A1 (ru) | 2014-05-13 | 2017-04-28 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
-
2016
- 2016-10-05 JP JP2018536719A patent/JP7132848B2/ja not_active Expired - Fee Related
- 2016-10-05 EA EA201890623A patent/EA201890623A1/ru unknown
- 2016-10-05 BR BR112018006572A patent/BR112018006572A2/pt not_active Application Discontinuation
- 2016-10-05 TW TW105132272A patent/TW201722422A/zh unknown
- 2016-10-05 AU AU2016336351A patent/AU2016336351A1/en not_active Abandoned
- 2016-10-05 CN CN201680069308.9A patent/CN108472376A/zh active Pending
- 2016-10-05 WO PCT/US2016/055594 patent/WO2017062520A1/en not_active Ceased
- 2016-10-05 EP EP16782374.9A patent/EP3359196B1/en active Active
- 2016-10-05 MX MX2018004112A patent/MX2018004112A/es unknown
- 2016-10-05 MA MA047474A patent/MA47474A/fr unknown
- 2016-10-05 US US15/765,980 patent/US20180280397A1/en not_active Abandoned
- 2016-10-05 KR KR1020187012285A patent/KR20180058824A/ko not_active Withdrawn
- 2016-10-05 CA CA3000851A patent/CA3000851A1/en not_active Abandoned
-
2018
- 2018-04-04 IL IL258494A patent/IL258494A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smyth et al. | Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| Jafari et al. | HSP90 and co-chaperones: impact on tumor progression and prospects for molecular-targeted cancer therapy | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| Healy et al. | The importance of Ras in drug resistance in cancer | |
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| JP2020531447A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| JP2017530950A5 (enExample) | ||
| Singh et al. | Profiling pathway‐specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): Favorable activity of targeting EGFR‐ErbB2 signaling with lapatinib | |
| JP2016533379A5 (enExample) | ||
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2022533578A5 (enExample) | ||
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2016528162A5 (enExample) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2016528246A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| JP2011515397A5 (enExample) | ||
| Zhang et al. | The renewed battle against RAS-mutant cancers | |
| JP2015511226A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний |